NASDAQ$BBIO
Bridgebio Pharma Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
BridgeBio Pharma reported a significant increase in revenue, supported by the commercial launch of Attruby, while experiencing continued net losses due to high operating expenses.
BridgeBio Pharma reported Q4 2024 revenue of $5.9 million, a significant increase from the prior year period, primarily driven by the first commercial sales of Attruby in the U.S. The company faced a net loss of $265.1 million, attributed to increased SG&A expenses related to commercialization efforts. Operating costs surged due to higher marketing and sales expenses, while cash and cash equivalents reached $681 million. The company continues to progress its pipeline with multiple Phase 3 studies advancing towards completion.
- Revenue increased to $5.9 million from $1.7 million in Q4 2023, driven by Attruby's first commercial sales.
- Net loss widened to $265.1 million, reflecting increased SG&A and R&D costs.
- Cash and cash equivalents rose to $681 million, strengthening liquidity.
- Attruby achieved significant regulatory milestones, including EU approval under the name BEYONTTRA.
Headline financials
Revenue & EPS history
Bridgebio · Revenue · Quarterly
$5.88M
Revenue by segment
Bridgebio · $100K total across 1 segment · Q2 2023
- License and Services Revenue$100K—100.0%
Forward guidance
BridgeBio expects continued revenue growth from Attruby while focusing on advancing late-stage clinical programs. Regulatory milestones in Europe and Japan are anticipated to contribute to financial performance.
Tailwinds
- Attruby's commercial launch is gaining traction with over 1,000 prescriptions filled.
- EU approval for BEYONTTRA brings milestone payments and future royalties.
- Strong liquidity position with over $681 million in cash.
- Multiple Phase 3 clinical trials are advancing towards completion in 2025.
- Additional regulatory approvals in Japan expected in 1H 2025.
Headwinds
- Net losses remain high due to increasing SG&A and R&D expenses.
- Operating expenses continue to climb, driven by commercialization costs.
- Revenue from Attruby remains modest at $2.9 million in Q4 2024.
- Future funding needs may arise to sustain R&D efforts.
- Market conditions and reimbursement policies could impact long-term sales.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.5%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.3%
Avg return
30 days after
48%
13 / 27 earnings
Positive
+40.9%
Q2 2022
Best reaction
-21.9%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | -3.2% | -0.7% | |
| Q4 2025 | -2.8% | -4.1% | +2.0% | |
| Q3 2025 | -4.9% | -7.9% | +8.1% | |
| Q1 2025 | +5.3% | +4.9% | -6.0% | |
| Q4 2024 | +1.4% | -5.3% | -4.2% | |
| Q3 2024 | -5.1% | -9.2% | +5.9% | |
| Q2 2024 | +0.9% | -4.2% | +7.3% | |
| Q1 2024 | +3.0% | +2.8% | +3.6% | |
| Q4 2023 | -0.5% | +4.6% | -13.4% | |
| Q3 2023 | +8.2% | +10.3% | +16.1% | |
| Q2 2023 | -2.3% | +0.8% | -4.4% | |
| Q1 2023 | -5.0% | -4.4% | -1.0% | |
| Q4 2022 | -4.7% | -6.6% | +21.8% | |
| Q3 2022 | -1.1% | -7.0% | -4.8% | |
| Q2 2022 | +40.9% | +39.7% | +26.7% | |
| Q1 2022 | -21.9% | -29.5% | -15.9% | |
| Q4 2021 | +7.6% | +13.9% | +41.1% | |
| Q3 2021 | +6.8% | +2.0% | -22.8% | |
| Q2 2021 | +2.4% | -1.1% | -2.3% | |
| Q1 2021 | -9.3% | -7.2% | +9.5% | |
| Q4 2020 | +4.9% | -1.8% | -9.8% | |
| Q3 2020 | -1.6% | +0.3% | +30.4% | |
| Q2 2020 | +1.4% | +0.2% | +16.2% | |
| Q1 2020 | -6.8% | +6.1% | -12.7% | |
| Q4 2019 | +2.2% | -9.3% | -21.3% | |
| Q3 2019 | +22.1% | +26.2% | +49.0% | |
| Q2 2019 | +0.0% | +4.8% | -3.2% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro